Syenex focuses on advancing biotechnological solutions through innovative drug delivery systems and cell engineering technologies. Their offerings include optimized enveloped vector surface compositions that enable high-efficiency, cell type-specific delivery, particularly for T cells. This technology is designed to enhance the effectiveness of therapeutic interventions by ensuring that the right cells receive the right treatments. Additionally, Syenex provides retroviral integrase delivery systems that are compatible with various programmable cell engineering payloads, allowing for greater flexibility and precision in therapeutic applications.

The company emphasizes the importance of scalability and regulatory support in the development of its technologies. By integrating Contract Development and Manufacturing Organization (CDMO) capabilities, Syenex streamlines the transition from pre-clinical prototyping to clinical validation. Their commitment to universal access to innovation ensures that drug developers can leverage a continuously improving catalog of cell engineering and delivery technologies, ultimately enabling more impactful therapeutic solutions and improving patient outcomes.

United States

Syenex is a synbio technology company that provides genetic medicine developers with access to best-in-class targeted delivery technologies (ex vivo & in vivo). Our goal is to accelerate clinical impact for developers of curative cell and gene therapies

1801 maple ave, evanston, illinois, united states, 60201-3149

Syenex

Company Details